Share your thoughts on our News & Insights section. Complete our survey to help us improve.
Derren Nathan

Derren Nathan

Head of Equity Research

Derren leads our Equity Research team with more than 15 years of experience in his field. Derren enjoys exploring the complex pharmaceutical sector and presenting share ideas for retail investors. He focuses on identifying exceptional companies poised for long-term success through outstanding customer propositions, translating into potential market-beating growth or sustainable dividends.

Covers

Share research and insight

Latest content from Derren

February 2025

Next week on the stock market
28th February 2025
NVIDIA: another earnings beat in final quarter
27th February 2025
CVS Group: UK drag continued in first half
27th February 2025
Haleon: launches new buyback with profits in line with estimates
27th February 2025
BP: financial strength prioritised in strategic reset
26th February 2025
Alibaba: unveils ambitious AI investment plans
25th February 2025
Croda International: strategic progress in a challenging 2024
25th February 2025
Smith & Nephew: 2024 beats lowered guidance
25th February 2025
Next week on the stock market
21st February 2025
Next week on the stock market
14th February 2025
British American Tobacco: final results and outlook reflect challenging market
13th February 2025
RELX: 2024 meets forecasts, further growth expected this year
13th February 2025
Heineken: buyback launched after earnings beat
12th February 2025
FTSE 100 nears record highs – 3 share ideas
12th February 2025
Entain: Gavin Isaacs steps down as CEO
11th February 2025
Coca-Cola: delivers strong Q4 performance with double digit growth
11th February 2025
BP: Q4 profits slump with buybacks under review
11th February 2025
McDonalds: Q4 revenues flat as US diners tighten belt
10th February 2025
Compass: strong start to the year
6th February 2025
Eli Lilly: 2024 result and 2025 guidance both in-line
6th February 2025
AstraZeneca: strong final quarter drives full year revenue beat
6th February 2025
AMD: Strong Q4 but Data Center outlook disappoints
5th February 2025
Entain: BetMGM on course for breakeven point in 2025
5th February 2025
PayPal: Q4 profits beat forecasts, profit outlook disappoints
5th February 2025
Novo Nordisk: GLP1’s drive strong 2024 growth
5th February 2025
GSK: enters 2025 in good health, launches £2bn buyback
5th February 2025
Pfizer: 2025 guidance re-iterated after strong fourth quarter
4th February 2025
Diageo: tariff impacts overshadow first half progress
4th February 2025

January 2025

Baker Hughes: strong Q4 supported by demand for gas technology
31st January 2025
Visa: festive spending drives strong first quarter
31st January 2025
Chevron: refining margins weigh on Q4 results
31st January 2025
Mastercard: ends 2024 with a strong quarter
30th January 2025
Shell: fourth quarter misses forecasts, but cash flows stay strong
30th January 2025
CVS Group: UK remains challenging, expansion down-under continues
30th January 2025
Microsoft: second quarter ahead of forecasts but third quarter guidance disappoints.
30th January 2025
US smaller companies set for success? – 3 share ideas
29th January 2025
ASML: 2025 guidance unchanged after strong fourth quarter
29th January 2025
United Utilities: full-year guidance intact, £13bn investment plan approved
29th January 2025
Dowlais: recommends merger with AAM
29th January 2025
NVIDIA: DeepSeek sparks fears around demand for high-end chips
28th January 2025
NVIDIA versus DeepSeek – why have US tech stocks fallen?
28th January 2025
Verizon: Q4 broadly in line, gradual growth expected in 2025
24th January 2025
Next week on the stock market
24th January 2025
J D Wetherspoon: robust H1 sales, braces for higher labour costs
22nd January 2025
Trump takes office as US president – 3 share ideas that could benefit
20th January 2025
3 healthcare stocks at the forefront of change
16th January 2025
TSMC: fourth quarter numbers exceed expectations
16th January 2025
Whitbread: UK trading stabilises after weak Q3, cost inflation looms
16th January 2025
Eli Lilly: 2024 revenue guide lowered again
15th January 2025
Mitchells & Butlers: Festive trading drives strong first quarter
15th January 2025
Entain: small upgrade to profit guidance
13th January 2025
Five shares to watch 2024 - how did they end the year?
3rd January 2025

November 2024

Mitchells & Butlers: full year profits recover, trading still robust
27th November 2024
How to invest in VCTs – plus some of the successes and failures
27th November 2024
Pets at Home: full-year guidance downgraded in subdued market
27th November 2024
Compass Group: 2024 in line, on course for more growth in 2025
26th November 2024
NVIDIA: Q3 results and Q4 guidance ahead of forecasts
21st November 2024
CVS Group: trading in-line despite soft UK demand
20th November 2024
Imperial Brands: full-year results in line, more growth expected
19th November 2024
Alibaba: Q2 results broadly in line as cash flows come under pressure
15th November 2024
Opportunity among the G20 leaders – 4 share ideas
15th November 2024
Next week on the stock market
15th November 2024
AstraZeneca: guidance raised again after Q3 beat
12th November 2024
Novo Nordisk: Q3 numbers mixed, Wegovy growth shines
6th November 2024
Trump wins the 2024 US Election – 3 US share ideas
6th November 2024

October 2024

Visa: Q4 estimates just beaten, more growth expected this year
31st October 2024
Eli Lilly: full year guidance reduced after Q3 miss
31st October 2024
Haleon: profit growth slows in Q3, full year guidance unchanged
31st October 2024
Shell: $3.5bn buyback after Q3 earnings beat
31st October 2024
GSK: full-year guidance confirmed despite weak Q3 vaccine sales
30th October 2024
AMD: another strong quarter but guidance disappoints
30th October 2024
BP: Q3 shareholder payouts on target as debt levels inch up
29th October 2024
McDonalds: third-quarter profit in-line despite sales disappointment
29th October 2024
PayPal: Q3 beats but guidance a little soft
29th October 2024
Pfizer: Q3 revenue beat, guidance upgraded
29th October 2024
Baker Hughes: Q3 sees strong profit growth but orders slip
23rd October 2024
Verizon: full-year guidance unchanged after flat Q3 revenue
22nd October 2024
Entain: small upgrade after strong Q3
17th October 2024
How to invest for income in the US stock market – 3 share ideas
17th October 2024
Whitbread: management in confident mood despite H1 growth stutter
16th October 2024
ASML: beats third-quarter guidance, but outlook disappoints
16th October 2024
China’s biggest stimulus package since COVID-19 – 3 share ideas to benefit
11th October 2024
Five shares to watch 2024 – where are they now?
10th October 2024
GSK: $2.2bn agreement to settle 93% of US Zantac cases
10th October 2024
Imperial Brands: trading in line, higher shareholder payouts targeted
8th October 2024

Social handles

@nathan_derren

CV

Head of Equity Research

Hargreaves Lansdown

July 2022 - Present

Head of Research

Hybridian LLP

July 2018 - July 2022 • 4 yrs 1 mo

Investment research

Hybridian LLP

Apr 2014 - July 2022 • 8 yrs 4 mos

In the press

Press articles quoting or featuring our experts and spokespeople. Hargreaves Lansdown is not responsible for these articles’ content and accuracy and may not share the views of the author or publication listed below.

dailymail.co.uk
Chancellor Jeremy Hunt's plan to sell off NatWest shares 'could cost taxpayers £28bn'
morningstar.com
Traders boost bets on mid-2024 rate cut by Bank of England as U.K. jobs market cools
thisismoney.co.uk
Analysts eye more M&A for Britain's hospitality sector